SciBase Secures Full Funding for Rights Issue

The guarantee, formalized on September 25, 2026, accounts for roughly 42 percent of the total offering. This commitment complements existing subscription undertakings from major shareholders—including Ribbskottet AB, Castle Biosciences Inc, and Life Science Invest Fund 1 ApS—which collectively cover the remaining 58 percent, or SEK 33.3 million. By securing these agreements, SciBase has effectively eliminated the funding gap for its current rights issue without relying on bank guarantees or pledged assets.

Investors are currently participating in the rights issue at a subscription price of SEK 15 per share, with the subscription period closing on September 29, 2026. Bergs Securities has further solidified its position by entering into sub-guarantee agreements with a consortium of investors to cover the full extent of its commitment. The final outcome of the offering is expected to be announced on or around October 1, 2026, marking a significant step for the company as it continues to advance its Nevisense diagnostic platform.